DaVita Inc. Q1 2003 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 2003. DaVita Inc. operates dialysis centers and laboratories, providing renal care services. As of May 1, 2003, approximately 61.1 million shares of common stock were outstanding. The company is an accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Operating Revenues | $459.8 million | $427.7 million |
| Operating Income | $79.3 million | $76.8 million |
| Net Income | $36.4 million | $36.0 million |
| Diluted EPS | $0.52 | $0.40 |
| Operating Cash Flow | $80.6 million | $83.5 million |
| Cash and Equivalents (End of Period) | $305.0 million | $31.7 million |
| Total Debt (Long-term + Current) | $1.46 billion | $1.32 billion |
| Operating Margin | 17.3% | 18.0% |
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 7.5% year-over-year. Excluding non-continental U.S. operations divested in 2002, continental U.S. revenue grew 8.5%. This was driven by a 4.5% increase in dialysis treatments and a 2.0% increase in average reimbursement rates.
- Lab Revenue Impact: The Q1 2003 results included approximately $6 million in Medicare laboratory revenue. No such revenue was recognized in Q1 2002 due to payment suspensions by a third-party carrier regarding the Florida laboratory.
- Expense Increases: Dialysis center and lab expenses rose to 69% of revenue (from 68% in Q1 2002) due to higher pharmaceutical, insurance, and labor costs. Debt expense increased by $4.5 million to $19.5 million due to higher debt balances from the 2002 recapitalization.
- Liquidity Improvement: Cash and cash equivalents surged from $96.5 million at year-end 2002 to $305.0 million in Q1 2003, driven by net cash provided by financing activities of $148.7 million (primarily borrowings of $623.8 million against debt payments of $478.7 million).
Guidance, Outlook, and Risks
- 2003 Guidance: Management projects full-year 2003 operating income in the range of $300 million to $320 million. Non-acquired annual growth is expected to remain between 3.0% and 5.0%.
- Regulatory Contingencies:
- Florida Laboratory: A third-party carrier review of Medicare claims (1995–2001) remains ongoing. While $68.8 million was collected in late 2002, approximately $31.5 million in claims remain disputed. The carrier has suspended prepayment screens pending a utilization study.
- Government Inquiries: The U.S. Attorney's Office (Philadelphia) and the Office of Inspector General (OIG) are reviewing historical practices, billing procedures, and financial relationships with physicians (covering May 1996–May 2002). The DOJ has also requested information regarding the Florida and Minnesota laboratories.
- Key Risks: Potential reductions in private and government reimbursement rates; changes in EPO (Erythropoietin) reimbursement rules or clinical practices; and the risk of penalties or exclusion from government programs if regulatory reviews find wrongdoing.
Investor Verification Checklist
- Verify the status of the Florida laboratory Medicare dispute and the potential impact of the remaining $31.5 million in disputed claims on future revenue recognition.
- Monitor the outcome of the U.S. Attorney's Office and OIG investigations regarding billing practices and physician relationships.
- Assess the impact of potential changes to Medicare EPO reimbursement rates or the inclusion of EPO in the composite dialysis rate.
- Review the company's ability to maintain private payor mix and reimbursement rates amidst pressure from managed care plans.
- Confirm the timeline and success of the new information technology rollout, which poses a risk of billing disruption.